Tag: Medicines News
In persons with certain forms of adjuvant liver cancer, Roche reports that the Tecentriq + Avastin phase III IMbrave050 research lowers the likelihood of the cancer coming back.
Avastin (bevacizumab) plus Tecentriq (atezolizumab) showed a statistically significant improvement in recurrence-free survival (RFS) in patients with hepatocellular…
Registration Form
This will close in 0 seconds
